Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Analysis of Drug-Related Interstitial Lung Disease in Head and Neck Squamous Cell Carcinoma Patients: A Signal Detection Study

  • By

  • Jie Ju

  • Zhongfen Liu

  • Lin Cao

  • Lina Xia

  • Pei Zhang

  • Yanfei Wang

  • July 13, 2026

Share

  • 1

    A signal mining study analyzed drug-related interstitial lung disease (ILD) in head and neck squamous cell carcinoma (HNSCC) patients using the FAERS database.

  • 2

    The study included 513 patients, revealing that cetuximab, nivolumab, and pembrolizumab had definite positive ILD signals based on reporting odds ratio and information component.

  • 3

    Anti-EGFR monoclonal antibodies and PD-1/PD-L1 inhibitors were identified as drug classes with positive safety signals for ILD in HNSCC treatment.

  • 4

    The median time to onset of ILD was 32 days, indicating that ILD primarily occurs early in the treatment stage for HNSCC patients.

  • 5

    The study emphasizes the need for strengthened monitoring of ILD in clinical practice due to the serious nature of this adverse reaction.

Original Source(s)

Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study

  • by Jie Ju, Zhongfen Liu, Lin Cao, Lina Xia, Pei Zhang, Yanfei Wang

  • July 13, 2026

Related Content

Single-cell-derived ferroptosis signature predicts prognosis and therapy response in esophageal squamous cell carcinoma

First-line penpulimab combined with anlotinib achieves complete response in an elderly patient with occult lung squamous cell carcinoma: a case report

Foundation model-enhanced multimodal radiomics for predicting response to chemo-immunotherapy in advanced lung squamous cell carcinoma